• Rohto Pharmaceutical posted Q1 net sales of JPY 91.62 billion, up 11.8% year-on-year, while operating income rose 16.8% to JPY 13.66 billion.
• Ordinary income fell 10.1% to JPY 14.49 billion, while profit attributable to owners of parent slipped 9.5% to JPY 10.65 billion.
• Asia net sales climbed 19.7% to JPY 35.6 billion, while Europe more than doubled to JPY 6.68 billion; Japan rose 5.2% to JPY 42.86 billion.
• Management cited a reactionary drop in dividend income versus a year earlier, while highlighting strong Japan eyecare and skincare demand and solid Asia performance led by Eu Yan Sang.
• Full-year forecast was revised up to net sales of JPY 372.3 billion and operating income of JPY 45 billion, reflecting weaker yen assumptions and stronger-than-expected Q1 results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.